Market Spotlight: Cervical Cancer
|出版日||ページ情報||英文 34 Pages
|注目市場の分析：子宮頸がん Market Spotlight: Cervical Cancer|
|出版日: 2018年03月07日||ページ情報: 英文 34 Pages||
This Market Spotlight report covers the cervical cancer market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Datamonitor Healthcare estimates that in 2016, there were 556,200 incident cases of cervical cancer in females worldwide, and expects that number to increase to 609,500 incident cases by
2025. Incidence cases are highest in Asia, and lowest in the Oceania region. Roche's Avastin (bevacizumab) and Amgen's Mvasi (bevacizumab), which target vascular endothelial growth factor; Novartis's Hycamtin (topotecan hydrochloride), a topoisomerase I inhibitor; and Pinnacle's Photofrin (porfmer sodium), a photodynamic therapy, are the only marketed drugs available for cervical cancer. The majority of the marketed drugs are administered via the intravenous route.
Therapies in mid-to-late-stage development for cervical cancer focus on a variety of targets. The majority of the drugs in mid-tolate-stage development for cervical cancer are administered via the intravenous route, with the remainder being intramuscular, intranasal, subcutaneous, and oral.
High-impact upcoming events for drugs in the cervical cancer space include topline Phase II and Phase III trial results. Licensing and asset acquisition activity involving cervical cancer drugs has been weak during 2012-17, with only 11 deals over this time period. The $727.5m license agreement between Inovio and MedImmune for the exclusive rights to develop and market Inovio's INO-3112 was the largest deal during 2012-17.
The clinical trials distribution across Phase I-IV indicates that the majority of trials for cervical cancer have been in early and midphases of development, with 95% of trials in Phase I-II, and only 5% in Phase III-IV.
The US has a substantial lead in the number of cervical cancer clinical trials globally. The UK leads the major EU markets, while South Korea has the top spot in Asia.
Clinical trial activity in the cervical cancer space is dominated by ongoing trials. AstraZeneca and Roche have the highest number of ongoing clinical trials for cervical cancer, with 11 and eight ongoing trials, respectively.
AstraZeneca leads industry sponsors with the highest number of clinical trials for cervical cancer, followed by Roche.
9 Targeted therapy
14 Approvals by country
25 Alligator And Aptevo Seal Immuno-Oncology Pact
25 Advaxis Zips Listeria/Opdivo Combo Straight To Registrational Cervical Cancer Trial
32 Prescription Information